Journal Guide
Publishing in JAMA Oncology: Fit, Timeline & Submission Guide
Clinical oncology with methodological excellence: where rigorous science meets cancer care
Should you submit here?
Submit if jAMA Oncology has among the most stringent methodological standards in oncology. Be careful if jAMA Oncology's statistical review is thorough.
20.1
Impact Factor (2024)
~8%
Acceptance Rate
~21 days
Time to First Decision
Submission guide
JAMA Oncology submission guide
A package-readiness guide to JAMA Oncology covering Key Points, structured abstract discipline, endpoint logic, and what must be stable before submission.
Journal assessment
Is JAMA Oncology a Good Journal? Fit Verdict
A practical JAMA Oncology fit verdict for authors deciding whether the manuscript can change physician practice in oncology broadly enough for the JAMA Network.
Desk rejection
how to avoid desk rejection at JAMA Oncology
how to avoid desk rejection at JAMA Oncology. Practical guidance for JAMA Oncology, plus what authors should do next. See how to avoid it.
What JAMA Oncology Publishes
JAMA Oncology combines the American Medical Association's commitment to clinical excellence with specialized oncology expertise. They want methodologically rigorous studies that advance cancer care through high-quality clinical research, outcomes analysis, and epidemiology.
- Clinical trials with rigorous methodology and clear practice implications
- Outcomes research that informs cancer care quality and delivery
- Cancer epidemiology studies with population-level insights
- Health services research addressing cancer care access and quality
- Methodological innovations in cancer research design and analysis
Editor Insight
“JAMA Oncology serves practicing oncologists who need methodologically sound evidence to guide patient care. We want research that's so well-designed and clearly presented that it becomes the standard reference for clinical decision-making.”
What JAMA Oncology Editors Look For
Exceptional methodological rigor
JAMA Oncology has among the most stringent methodological standards in oncology. Every aspect of study design, analysis, and reporting must be bulletproof.
Clinical trial excellence
Phase 3 trials with clear primary endpoints, appropriate statistics, and practice-changing results. Protocol adherence and reporting standards are scrutinized intensely.
Outcomes research that matters
Studies that show how we can deliver better cancer care. Quality measures, survival outcomes, and real-world effectiveness are key themes.
Population-level perspective
Research that addresses cancer care across populations, not just individual patients. Disparities, access, and health equity considerations are valued.
Immediate clinical applicability
Like all JAMA journals, the focus is on research that practicing oncologists can use. Academic exercises without clinical relevance face skepticism.
Transparent and complete reporting
Full disclosure of methods, limitations, conflicts, and funding. Any hint of selective reporting or hidden data is fatal.
Why Papers Get Rejected
These patterns appear repeatedly in manuscripts that don't make it past JAMA Oncology's editorial review:
Methodological shortcuts or omissions
JAMA Oncology's statistical review is thorough. Underpowered studies, inappropriate analyses, or missing data handling will be caught and criticized.
Single-institution studies without broader validation
Results from one cancer center raise generalizability questions. Multi-site studies or validation in external cohorts strengthen claims significantly.
Incomplete trial reporting
CONSORT guidelines aren't suggestions. Missing flow diagrams, unreported outcomes, or protocol deviations without explanation damage credibility.
Overinterpreting secondary endpoints
If your primary endpoint didn't meet significance, spinning secondary analyses as practice-changing doesn't work. Be honest about what you've proven.
Ignoring health equity implications
If your research has implications for cancer disparities or access to care, address this explicitly. JAMA Oncology increasingly values equity perspectives.
Weak clinical implications section
How does this change practice? What should oncologists do differently? If you can't articulate clear clinical implications, rethink your submission.
Does your manuscript avoid these patterns?
The Free Readiness Scan reads your full manuscript against JAMA Oncology's criteria and flags the specific issues most likely to cause rejection.
Insider Tips from JAMA Oncology Authors
Statistical review is exceptionally thorough
JAMA Oncology employs dedicated biostatisticians who will scrutinize every analysis. Get statistical review before submission, not after.
Negative trials are welcomed if well-designed
Definitive negative results that prevent adoption of ineffective treatments are valued. Don't spin negative results; embrace them if methodologically sound.
Real-world evidence studies are increasingly important
Registry studies, administrative database analyses, and population-based cohorts that complement trial data are in demand.
Health equity research gets editorial attention
Studies addressing cancer disparities, rural access, or socioeconomic barriers to care align with JAMA's social justice mission.
Clinical guidelines influence often cited
Studies that directly inform NCCN, ASCO, or other guidelines get extra attention. Frame your work in terms of guideline implications.
Patient-reported outcomes are increasingly required
Quality of life, functional status, and patient experience measures strengthen clinical trial submissions significantly.
Meta-analyses need exceptional rigor
If submitting systematic reviews, adherence to PRISMA guidelines and thorough search strategies are essential.
AMA connections don't hurt but aren't required
Work affiliated with AMA initiatives may get extra consideration, but methodological excellence trumps politics.
The JAMA Oncology Submission Process
Presubmission inquiry (rarely used)
Response within 1 week if submittedJAMA Oncology prefers full submissions. Inquiries mainly for highly unusual study types.
Full submission
Initial decision ~21 daysComplete manuscript with emphasis on methodological rigor and clinical relevance. Structured abstract required.
Editorial and statistical review
~2-3 weeksConcurrent editorial and methodological assessment. High desk rejection rate for methodologically weak studies.
Peer review
3-4 weeksClinical oncologists and methodological experts. Focus on rigor, clinical significance, and practice implications.
Revision
Authors expected to respond efficientlyRevision requests typically focused on specific methodological concerns or clinical interpretation issues.
JAMA Oncology by the Numbers
| 2024 Impact Factor(Clarivate JCR) | 28.4 |
| Submissions per year | ~2,800 |
| Acceptance rate | ~8% |
| Desk rejection rate | ~70% |
| Time to first decision | 21 days median |
| Post-review acceptance | ~25% of reviewed |
| Monthly publication | 12 issues/year |
| AMA oncology membership | Part of larger AMA community |
Before you submit
JAMA Oncology accepts a small fraction of submissions. Make your attempt count.
Start with the Free Readiness Scan. Unlock the Full AI Diagnostic for $29. If you need deeper scientific feedback, choose Expert Review. The full report is calibrated to JAMA Oncology.
Article Types
Original Investigation
3,500 wordsFull clinical research reports with practice implications
Brief Report
1,500 wordsConcise reports of important clinical findings
Review
4,000 wordsSystematic reviews and meta-analyses
Viewpoint
1,200 wordsOpinion pieces on cancer care and policy
Landmark JAMA Oncology Papers
Papers that defined fields and changed science:
- Radical vs. conservative surgery in breast cancer - long-term outcomes (Fisher et al., 2017)
- Immune checkpoint inhibitor toxicity - population-based analysis (Puzanov et al., 2017)
- Cancer screening in older adults - guideline recommendations (Wolf et al., 2018)
- Financial toxicity of cancer care - national survey (Zafar et al., 2019)
- Telemedicine in oncology during COVID-19 - practice patterns (Lonergan et al., 2020)
Preparing a JAMA Oncology Submission?
Get pre-submission feedback from reviewers who've published in JAMA Oncology and know exactly what editors look for.
Run Free Readiness ScanNeed expert depth? See Expert Review Options
Primary Fields
Browse by Field
Related Journal Guides
- Publishing in The Lancet
- Publishing in New England Journal of Medicine
- Publishing in Cancer Cell
- Publishing in Journal of Clinical Oncology
- Publishing in The Lancet Oncology
Latest Journal-Specific Guides
- Submission guideJAMA Oncology submission guideA package-readiness guide to JAMA Oncology covering Key Points, structured abstract discipline, endpoint logic, and what must be stable before submission.
- Journal assessmentIs JAMA Oncology a Good Journal? Fit VerdictA practical JAMA Oncology fit verdict for authors deciding whether the manuscript can change physician practice in oncology broadly enough for the JAMA Network.
- Desk rejectionhow to avoid desk rejection at JAMA Oncologyhow to avoid desk rejection at JAMA Oncology. Practical guidance for JAMA Oncology, plus what authors should do next. See how to avoid it.
- Review timelineJAMA Oncology Review Time: What Authors Can Actually ExpectJAMA Oncology often tells authors relatively quickly whether a paper belongs in top-tier clinical oncology, but the real submission question is methodological and clinical consequence, not just speed.
More Guides for This Journal
- Acceptance rateJAMA Oncology Acceptance Rate: What Authors Can UseJAMA Oncology is better judged through practice-changing clinical evidence than through a guessed acceptance percentage. The current official signal is clearer than it used to be.
- Impact factorJAMA Oncology Impact Factor 2026: 20.1, Q1, Rank 14/326JAMA Oncology impact factor is 20.1 with a 5-year JIF of 24.7. See the rank, trend, and what that number means before submission.
- Publishing costsJAMA Oncology APC and Open Access: Current AMA Pricing and When the Fee Is Worth ItJAMA Oncology's current APC is $6,000 for eligible gold OA articles. Standard publication is free, with delayed access after 12 months.
- Submission processJAMA Oncology submission processA workflow-focused JAMA Oncology submission process guide covering what happens after upload, what triage is testing, and where papers lose time.
- Manuscript prepJAMA Oncology Cover Letter: What Editors Actually Need to SeeJAMA Oncology editors are screening for clinically important oncology evidence that can survive close methodological scrutiny. A strong cover letter makes both obvious fast.
- Publishing guideIs JAMA Oncology Indexed in PubMed? Yes, and MEDLINE Is ActiveJAMA Oncology is indexed in PubMed and currently indexed for MEDLINE, which matters because broad oncology papers need search visibility across clinical and academic readers.
Ready to submit to JAMA Oncology?
A desk rejection costs months. Get expert feedback before you submit, from scientists who know exactly what JAMA Oncology editors look for.
Avoid Desk Rejection
Get expert pre-submission review before you submit to JAMA Oncology. 3-7 day turnaround.
Manuscript Rejected?
Expert revision help to strengthen your manuscript and resubmit with confidence.
Reviewer Response Help
Get expert guidance crafting your response to JAMA Oncology reviewers.
Reference library
Compare JAMA Oncology with the broader publishing context
This journal guide is the best starting point for JAMA Oncology. The reference library covers the surrounding questions authors usually ask next: whether the package is ready, what drives desk rejection, how neighboring journals compare, and what the submission constraints look like across the field.
Checklist system / operational asset
Elite Submission Checklist
A flagship pre-submission checklist that turns journal-fit, desk-reject, and package-quality lessons into one operational final-pass audit.
Flagship report / decision support
Desk Rejection Report
A canonical desk-rejection report that organizes the most common editorial failure modes, what they look like, and how to prevent them.
Dataset / reference hub
Journal Intelligence Dataset
A canonical journal dataset that combines selectivity posture, review timing, submission requirements, and Manusights fit signals in one citeable reference asset.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Need field-expert depth? See Expert Review Options